GW Pharmaceuticals [1] is planning to start human trials of a new obesity treatment derived from cannabis. A variety of drug developers, including Sanofi-Aventis, are working to develop therapies that snap the body's craving for food when they smoke cannabis. And researchers at the U.K. company say that cannabis itself contains clues to controlling obesity. Various ingredients in cannabis, they say, can both stimulate and suppress hunger.
- here's the report [2] from MedIndia
Related Articles:
Solvay earns $25M as obesity drug advances. Report [3]
EMEA committee recommends Acomplia of obesity. Report [4]
FDA approves synthetic cannabis. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/spotlight-new-sativex-trial-planned/2006-08-09
[2] http://www.medindia.net/news/view_news_main.asp?x=17945
[3] http://www.fiercebiotech.com/story/solvay-earns-25m-as-obesity-drug-advances/2006-12-08
[4] http://www.fiercebiotech.com/story/emea-committee-recommends-acomplia-of-obesity/2006-04-28
[5] http://www.fiercebiotech.com/story/spotlight-fda-approves-synthetic-cannabis/2006-05-16